Oncotelic Therapeutics, Inc. 8-K

What Happened

• On March 23, 2026, Oncotelic Therapeutics, Inc. announced that Sapu Nano — a company in which Oncotelic holds a minority interest — will present new toxicology data for evorlimus at the Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo in San Diego. The company furnished a press release and the poster presentation with the Form 8-K filed March 30, 2026. The filing notes this information is being furnished (not “filed”) under the Securities Exchange Act.

Key Details

• Announcement date: March 23, 2026; Form 8-K filed March 30, 2026.
• Event: SOT 2026 Annual Meeting and ToxExpo in San Diego, California.
• Topic: New toxicology data on evorlimus from Sapu Nano.
• Oncotelic’s position: minority investor in Sapu Nano (no funding or financial amounts disclosed in this filing).

Why It Matters

• Investors should note Oncotelic’s minority stake ties its outlook partly to Sapu Nano’s progress; new toxicology data can influence the perceived development and risk profile of evorlimus-related programs.
• The filing itself is informational (furnished, not filed), so it provides disclosure of the presentation but does not change Oncotelic’s reported financials or governance in this document.